• Home |
  • Reports |
  • Global Lipid-Nanoparticle Based Genomic Medicines Market: By Type (Liposome-based Nanoparticles, Mic....

Global Lipid-Nanoparticle Based Genomic Medicines Market: By Type (Liposome-based Nanoparticles, Micelle-based Nanoparticles, Lipid-Coated Nanoparticles); By Application (Cancer Treatment, Infectious Diseases, Genetic Disorders, Cardiovascular Diseases, Others); By Therapeutic Payload (mRNA-based Therapeutics, siRNA-based Therapeutics, miRNA-based Therapeutics, Others); By End-User (Hospitals, Biopharmaceuticals Companies, Research Institute); By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East, and Africa) Global Industry Analysis, COVID-19 Impact, and Industry Forecast, 2018-2032.

  • We provide customized solutions to cater to your specific requirement services any region, product, or any specific market segment.
Market Overview/Outlook (2022 to 2032)

The global market for Lipid-Nanoparticle-Based Genomic Medicines is expected to grow between 2023 and 2032 due to effective drug delivery, advancements in genomic medicine, rising incidence of genetic disorders, precision medicine, and personalized therapies.

The Global Lipid-Nanoparticle-Based Genomic Medicines Market was valued at USD 16.23 Billion in 2022 and is projected to reach USD 36.50 Billion by 2032, registering a CAGR of 8.40 % for the forecast period 2023-2032.

Global Lipid-Nanoparticle-Based Genomic Medicines Market Drivers
  • Effective Drug Delivery: Target cells can receive genomic medicines, such as RNA-based therapeutics, efficiently through the use of lipid nanoparticles as carriers. They improve these medications' stability and bioavailability, which makes it easier for them to be effectively delivered to particular tissues.
  • Advancements in Genomic Medicine: The need for efficient delivery systems has been fueled by ongoing developments in genomic medicine, such as the creation of gene-editing technologies and RNA-based therapeutics. Lipid nanoparticles present a viable approach to the delivery of these innovative treatments.
  • Rising Incidence of Genetic Disorders: The increasing prevalence of genetic disorders and rare diseases has created a need for innovative genomic medicines. Nucleic acid-based therapies that target and address the underlying causes of genetic disorders, such as RNA interference (RNAi) and CRISPR-based treatments, can be delivered via lipid nanoparticles.
  • Precision Medicine and Personalized Therapies: The development of personalized therapies and precision medicine is greatly aided by lipid nanoparticles. They make it possible for genomic medicines to be delivered precisely, enabling more individualized and successful treatment plans based on patient genetic profiles.
Global Lipid-Nanoparticle Based Genomic Medicines Market – Merger and Acquisitions
  • Alexion, AstraZeneca Rare Disease to Acquire LogicBio Therapeutics to Accelerate Growth in Genomic Medicine (2022)
Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, Mass.-based LogicBio Therapeutics, Inc., a pioneering genomic medicine company. The proposed acquisition aims to rapidly accelerate Alexion’s growth in genomic medicines through LogicBio’s unique technology, experienced rare disease R&D team, and expertise in pre-clinical development.
  • Croda International Plc acquired Avanti Polar Lipids (2020)
Croda International Plc acquired Avanti Polar Lipids, enhancing its R&D capabilities in drug delivery through Avanti’s expertise in innovative lipid-based products. This strategic acquisition bolsters Croda’s position in advancing technologies for efficient and targeted drug delivery systems.
  • Gattefosse Breaks Ground on First North American Manufacturing Facility (2022)
Gattefosse has announced the groundbreaking on its first North American manufacturing facility in Lufkin city, Texas. The facility will manufacture lipid-based specialty ingredients for the personal care and pharmaceutical industries. Operations at the plant are expected to begin in 2024.
  • Precision NanoSystems joins Danaher’s Life Sciences Platform (2021)
Precision NanoSystems (PNI) has been acquired by Danaher Corporation’s Life Sciences platform. PNI is a global leader in technologies and solutions for the development of genetic medicines, including mRNA vaccines and therapeutics. PNI will join Danaher’s Life Sciences platform and will be complementary to other businesses in the platform, including Cytiva and Pall.
  • Evonik invests US$220 million in partnership with the U.S. Government to build a new lipid production facility for mRNA-based therapies in the U.S. (2022)
Evonik, one of the world's leading providers of drug delivery technologies, is building a new, highly flexible, global-scale production facility for pharmaceutical lipids in the United States. The new plant at Evonik’s Tippecanoe site in Lafayette, Indiana, will broadly position the Group for future growth in novel mRNA-based therapies beyond COVID-19 vaccines and strengthen its leading role as a strategic partner for innovative pharmaceutical companies worldwide. Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025.

Challenges Impacting the Global Lipid-Nanoparticle-Based Genomic Medicines Market
  • Safety Issue: Notwithstanding developments in lipid nanoparticle formulations, a general acceptance of these delivery systems may be impeded by worries about long-term safety and possible adverse effects. For market participants, addressing safety concerns and guaranteeing regulatory compliance are crucial tasks.
  • Complex Production Procedure: Lipid nanoparticle production can involve intricate procedures and specialized knowledge. It can be difficult to create scalable and repeatable manufacturing processes, and problems with these processes can affect how efficiently and affordably genomic medicines are produced overall.
  • Limited Lipid Nanoparticle Stability: Lipid nanoparticle stability can be a problem, particularly when they are being stored and transported. Stability concerns can shorten the shelf life of lipid-based formulations, which is crucial for maintaining structural integrity over time and guaranteeing the effectiveness of genomic medicines.
  • Awareness and behavior of consumers: Some patients may experience immune responses in response to lipid nanoparticles, which could result in the therapeutic payload being cleared or in unfavorable side effects. Effectively managing immunogenicity poses a challenge, and mitigating the likelihood of immune responses is crucial for the successful application of genomic medicines based on lipid nanoparticles.
Report Scope:
Global Lipid-Nanoparticle-Based Genomic Medicines Market 2022
Global Revenue (USD Billion) 16.23
CAGR – (2023-2032) 8.40%
Segment covered By Type, By Therapeutic Payload, By End-User, By Application & By Region
Regions Covered North America; Europe; Asia Pacific; Latin America; MEA
Country Scope U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; India; Japan; China; Southeast Asia, Brazil; Argentina; GCC Countries, UAE, and South Africa.
Key Company Profiled Key companies profiled in the Lipid-Nanoparticle Based Genomic Medicines Market report include Moderna Inc., Pfizer Inc., BioNTech SE, Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals Inc., CureVac N.V., Lipocalyx, Acuitas Therapeutics, Precision NanoSystems Inc., IONTAS Limited, Genevant Sciences, Roche Holding AG, Alnylam Pharmaceuticals Inc., SiO2 Materials Science, Ethris GmbH and others.
Customization scope Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope
Pricing and purchase options Avail customized purchase options to meet your exact research needs. Explore purchase options
Category-wise Analysis:

By Type:

  • Lipid-coated Nanoparticles: LNPs are appropriate for a variety of therapeutic applications because they can encapsulate a broad range of therapeutic payloads, such as mRNA, siRNA, miRNA, and plasmids. By functionalizing LNPs with targeting ligands, payloads can be delivered to diseased cells or tissues with specificity, increasing efficacy and minimizing side effects. Compared to other lipid nanoparticle types, LNPs provide the encapsulated payloads with better stability and protection, which boosts delivery efficiency. Several LNP-based drugs, such as COVID-19 mRNA vaccines and siRNA-based therapeutics, are already marketed and be safe and effective in clinical settings.
  • Liposome-based Nanoparticles: Because liposomes are made of phospholipids, which are similar to cell membranes, the body can tolerate them well, reducing the possibility of toxicity or immunological reactions. Their structure makes it possible to encapsulate therapeutic payloads (such as siRNA and mRNA) and shield them from degradation while they are being transported to target sites and circulated. Targeting molecules or ligands can be added to the liposome surface to increase the uptake of particular cells or tissues, enabling targeted delivery and increased therapeutic efficacy.
  • Micelle-based Nanoparticles: Generally speaking, amphiphilic molecules with high biocompatibility form micellar bodies, which may allay toxicity worries. To safeguard delicate genetic payloads, micellar environments can be created. Micelles can be tailored for targeted delivery, just like LNPs. Micelle production may occasionally be more affordable than LNP production.

By Application:

  • Cancer Treatment: LNP-based therapies are presently being investigated in numerous clinical trials for a range of cancer types. In some cases, these trials have produced encouraging early results. These treatments employ LNPs to deliver a variety of payloads, such as mRNA to encode therapeutic proteins, siRNA to silence genes that cause cancer, and gene editing tools to rectify genetic mutations linked to the development of cancer. By specifically targeting cancer cells, LNPs can be designed to minimize their negative effects on healthy tissues. A range of treatment modalities is made possible by the ability of LNPs to be loaded with various therapeutic payloads.
  • Infectious Diseases: LNPs are useful in preventing infectious diseases, as evidenced by the success of mRNA vaccines like Comirnaty and Spikevax, which use LNP technology to treat COVID-19. This achievement has spurred additional investigation and development of LNP-based vaccines against malaria, HIV, and influenza. In addition to vaccines, the infectious disease segment includes potential LNP-delivered therapeutics for treatment, including antibiotics, gene editing therapies that target pathogens, and antivirals. The potential market share is increased by this broader range of applications.
  • Genetic Disorders: Mutations in the DNA or RNA are frequently the cause of genetic disorders. Nucleic acid-based treatments, such as CRISPR-based gene editing instruments or RNA interference (RNAi), can be efficiently delivered via lipid nanoparticles. The goal of these treatments is to modify or fix the expression of the defective genes that cause hereditary diseases. Lipid nanoparticles offer fragile nucleic acid payloads a stable and safe haven. This guarantees the therapeutic material's integrity and bioavailability, particularly under the demanding circumstances of the body's biological environment.
  • Cardiovascular Diseases: Hyperlipidemia is a disorder marked by high blood lipid levels. RNA-based therapeutics can be delivered using lipid nanoparticles to treat this condition. By focusing on particular genes related to lipid metabolism, the risk of cardiovascular disorders linked to hyperlipidemia may be reduced. One of the main factors in cardiovascular disorders is inflammation. By modifying the expression of genes involved in the inflammatory response and possibly slowing the advancement of cardiovascular diseases, lipid nanoparticles can be used to deliver anti-inflammatory genomic medications.
Regional Analysis:

North America:
  • United States: The United States boasts an extremely sophisticated healthcare system, complete with a well-established regulatory framework that makes it easier to develop, test, and commercialize cutting-edge medical technologies such as lipid nanoparticles for genomic medicine. The United States is home to a large number of top biotechnology and pharmaceutical companies that specialize in drug delivery technologies and genomic medicine. These major players in the industry support market expansion by conducting research and developing new products. Clinical trials and regulatory approvals in the biotechnology and pharmaceutical industries are centered in the United States.
  • Canada: The biotechnology industry in Canada is expanding, with businesses specializing in the creation of cutting-edge treatments like genomic medicines. The existence of biotech companies that focus on lipid nanoparticle delivery systems may aid in the expansion of the market. Modern medical technology can be adopted more easily in an environment with a strong healthcare infrastructure. Genomic medicine integration into clinical practice can be facilitated by the presence of cutting-edge healthcare facilities and a skilled workforce.
Asia Pacific:
  • China: The biopharmaceutical sector in China has grown significantly. Increased investment and government support for pharmaceutical and biotechnology research have propelled advances in genomic medicine, including the application of lipid nanoparticles for drug delivery. China has been investing a lot of money in R&D, especially in the fields of genomics and life sciences. A strong market presence is a result of the emphasis on innovation and the creation of cutting-edge treatments, such as genomic medicines based on lipid nanoparticles. China faces many healthcare challenges due to its large and diverse population, including the high prevalence of different diseases.
  • India: Lipid nanoparticle-based genomic medicines can be developed and adopted more quickly through partnerships in genomic research and clinical trials between Indian research institutions, pharmaceutical companies, and foreign partners. Lipid nanoparticle-based treatments may be accepted and used more widely in India if efforts are made to raise public and healthcare professionals' knowledge of genomic medicine. Many diseases that are common in India, such as some cancers, infectious diseases, and genetic disorders, can be treated with lipid nanoparticle-based genomic medicine. Market expansion may be fueled by these therapies' applicability to the regional illness landscape.
  • Southeast Asia: The expansion of Southeast Asia's biotechnology sector may be a major factor in the development of genomic medicine. Lipid nanoparticles and other novel drug delivery systems may see more research and investment as the industry grows. Southeast Asia is rapidly developing its healthcare infrastructure and has emerged as a major destination for medical tourism. The market can expand as a result of the availability and affordability of cutting-edge medical treatments, such as genomic medicine given via lipid nanoparticle delivery.
  • Western Europe: Research and development in the healthcare industry is frequently given priority in Western European nations. Strong R&D funding encourages creativity and the creation of cutting-edge treatments, such as genomic medicine based on lipid nanoparticles. Advances in genomic medicine can be fueled by partnerships between Western European biotech companies, research centers, pharmaceutical companies, and academic institutions. Lipid nanoparticle-based therapeutics may be developed and brought to market as a result of these partnerships.
  • Eastern Europe: Lipid nanoparticle-based genomic medicine may flourish in Eastern Europe if legislation is supportive and government funding is available for the creation and application of novel medical treatments. Positive outcomes from clinical trials involving lipid nanoparticle-based genomic medicines conducted in Eastern Europe may encourage the region's adoption of these treatments. The creation and manufacturing of lipid nanoparticles may be made easier by Eastern European nations' improved access to cutting-edge technologies and highly trained labor force, which would support the market expansion for genomic medicine.
Latin America:
  • Brazil: The market would expand if lipid nanoparticle-based genomic medicine clinical trials were carried out in Brazil and these treatments received regulatory approval. Encouraging outcomes from clinical trials and regulatory backing bolster trust in these inventive treatment methodologies. Market adoption may be influenced by patients' and healthcare professionals' knowledge of the advantages of genomic medicine as well as their acceptance of lipid nanoparticle-based delivery systems. In this sense, campaigns for awareness and education may be helpful. Investments in the healthcare and life sciences industries can be attracted by economic stability and favorable conditions.
  • Mexico: Extensive research activities and ongoing clinical trials about lipid nanoparticles and genomic medicine in Mexico may help increase the acceptance and comprehension of these technologies within the healthcare system. Adoption may rise as a result of initiatives to inform medical professionals and the general public about the advantages of lipid nanoparticles in genomic medicine. Market expansion may be impacted by the population's capacity to pay for cutting-edge medical care and economic stability. There must be a market for genomic medicine solutions that can sustain them financially.
Middle East and Africa:
  • Middle East: The expansion of creative healthcare solutions might be aided by the Middle East's biotechnology and pharmaceutical industries. Lipid nanoparticles are being used in genomic medicine in a way that is consistent with global trends in drug delivery technologies. Progress in genomic medicine could be facilitated by regional research institutes and universities that specialize in genomics and medical research. Lipid nanoparticles can be used more effectively for drug delivery when they are the subject of local research and development projects.
  • Africa: Delivering RNA-based vaccines and treatments has demonstrated potential using lipid nanoparticles. Lipid nanoparticle application in the treatment of infectious diseases could be important given the prevalence of these diseases in some African regions. The adoption of cutting-edge medical technologies, such as lipid nanoparticles for genomic medicine, may be facilitated by humanitarian efforts and initiatives aimed at enhancing healthcare in underserved areas. Advanced genomic medicine can be better understood and known by healthcare professionals in Africa through capacity-building initiatives and educational programs.
  • Australia and New Zealand: Because of their superior healthcare systems, Australia and New Zealand might see a rise in the demand for cutting-edge medical procedures like genomic medicine. Because lipid nanoparticles can deliver drugs efficiently, they can be included in these cutting-edge treatments. The development and uptake of lipid nanoparticle-based genomic medicines can be sped up by partnerships and collaborations between domestic and foreign pharmaceutical companies, academic institutions, and healthcare providers. The use of cutting-edge drug delivery technologies like lipid nanoparticles, along with patient acceptance and awareness of genomic medicine, is essential for commercial success.

List of Prominent Players:
  • Moderna Inc.
  • Pfizer Inc.
  • BioNTech SE
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals Inc.
  • CureVac N.V.
  • Lipocalyx
  • Acuitas Therapeutics
  • Precision NanoSystems Inc.
  • IONTAS Limited
  • Genevant Sciences
  • Roche Holding AG
  • Alnylam Pharmaceuticals Inc.
  • SiO2 Materials Science
  • Ethris GmbH
  • Others
Segmentation of Global Lipid-Nanoparticle-Based Genomic Medicines Market:

By Type:
  • Liposome-based Nanoparticles
  • Micelle-based Nanoparticles
  • Lipid-coated Nanoparticles
By Application:
  • Cancer Treatments
  • Infectious Diseases
  • Genetic Disorders 
  • Cardiovascular Diseases
  • Others
By Therapeutic Payload:
  • mRNA-based Therapeutics
  • siRNA-based Therapeutics
  • miRNA-based Therapeutics
By End-User:
  • Hospitals
  • Biopharmaceuticals Companies
  • Research Institutes
By Region:
  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia Pacific (China, Japan, India, Southeast Asia, Rest of APAC)
  • Latin America (Brazil, Argentina, Rest of Latin America)
  • Middle East & Africa (GCC Countries, UAE, Rest of MEA)
No Methodology
No Available